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Acute lymphoblastic leukemia (ALL) is the most com-
mon childhood cancer with incidence rate in USA and
Europe of 3.5 cases per 100 000 children. The overall
current cure rate is ~ 75% and around 25% of treated
children die from resistant disease, relapse or treatment
toxicities. Several single nucleotide polymorphisms
(SNPs) are known to be key determinators for interidivi-
dual differences in treatment resistance and toxic side
effects [1]. Because childhood ALL treatment protocols
include up to 13 different chemotherapeutic agents, it is
hard to evaluate the impact of individual SNPs. So far
focus has mainly been on the widely used glucocorticos-
teroids, methotrexate and thiopurines, or on metabolic
pathways and transport mechanisms that are common
to several drugs, such as the glutathione S-transferases.
However, beyond the thiopurine methyltransferase poly-
morphisms, the candidate-gene approach has not estab-
lished clear associations between polymorphisms and
treatment response.
Instead of single SNP or gene investigation, we have
designed a high- throughput assay for ~ 20 000 targeted
SNPs to explore combined gene- dosage effects. The
assay applies multiplexed targeted sequencing as a cost-
effective technique for genotyping. Such a multiple-SNP
assay will allow the investigation of effects mediated via
pathways where one of several SNPs (in the same or dif-
ferent genes) may lead to very similar clinical pheno-
types due to related molecular mechanisms. In selection
of genes, we have included those involved in
pharmacology, immunology, DNA-repair mechanisms,
mitosis activity genes, and genes that affect apoptosis,
neurotoxicity and thrombosis. We have also included
binding partners of key proteins from protein-protein
interaction data, and proteins known to interact with
the 13 compounds commonly used for treatment. The
selected SNPs target coding regions and known regula-
tory regions including predicted microRNA target sites.
The study will include up to 2000 children with ALL,
divided into a retrospective study (600-800 samples) and
a prospective study.
This poster will present current status and challenges
of the project and demonstrate the multiplexed targeted
sequencing as a cost-effective technique for genotyping.
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